With the new development of healthcare systems toward the Value Framework for reimbursement in the world, Real World Evidence (RWE) is becoming a more important to be used by decision making process for reimbursement authorities in Asian countries. At this critical point, it would be important to have a firm grasp on what evidence can be presented, as well as the acceptable, in the value framework for reimbursement. To support and promote this initiative, Asia Consortium Industry Committee has launched two related projects in Real World Data (RWD) development and Health Technology Assessment (HTA) requirements in Asia. At this forum, speakers will present the objectives, approaches, methods of these projects, and provide status updates, and expectation of the deliverables, with usefulness of the outcomes to support regional reimbursement decision making, especially for researchers who need to collect and provide the RWD evidences. The objectives are: • To assess HTA value evidence requirements in the Asian region via information on current HTA status in selected countries and their trend in 3-5 years. • To provide a data source platform to support RWE/RWD research in the region, by conducting a landscape evaluation of current information on the availability and accessibility of various existing RWD in Asia and performing a general quality assessment and contents evaluation of each type of the RWD. During the forum, reimbursement negotiation cases from selected countries with outcomes data communication and recommendation on the value framework to generate the right evidence will be provided. How RWD evidence generation meets the needs for growing HTA demand in Asia and how to incorporate RWE in market access strategies will also be discussed.